Matches in Nanopublications for { ?s ?p "[Despite the efficacy and superiority of EGFR TKIs over chemotherapy as first-line therapy, all patients will ultimately develop progressive disease, with a median of 9-13 months progression-free survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- NP1215886.RAWq8Z0B5EQVX2geXxwOalavr0UTizpnDbUXcq0Ii6JSQ130_assertion description "[Despite the efficacy and superiority of EGFR TKIs over chemotherapy as first-line therapy, all patients will ultimately develop progressive disease, with a median of 9-13 months progression-free survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1215886.RAWq8Z0B5EQVX2geXxwOalavr0UTizpnDbUXcq0Ii6JSQ130_provenance.
- NP1215887.RA-RmbFkgd-GAZyK6hui-CVXT2JNka2GAoIQHNIkv9APs130_assertion description "[Despite the efficacy and superiority of EGFR TKIs over chemotherapy as first-line therapy, all patients will ultimately develop progressive disease, with a median of 9-13 months progression-free survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1215887.RA-RmbFkgd-GAZyK6hui-CVXT2JNka2GAoIQHNIkv9APs130_provenance.